title: Lessons learned from the clinical development and market authorization of Glybera.
authors.affiliation: Neuroscience Graduate Group, University of Pennsylvania, Philadelphia, PA 19104, USA.
authors.forename: Laura M
authors.initials: LM
authors.lastname: Bryant
authors.forename: Devin M
authors.initials: DM
authors.lastname: Christopher
authors.forename: April R
authors.initials: AR
authors.lastname: Giles
authors.forename: Christian
authors.initials: C
authors.lastname: Hinderer
authors.forename: Jesse L
authors.initials: JL
authors.lastname: Rodriguez
authors.forename: Jenessa B
authors.initials: JB
authors.lastname: Smith
authors.forename: Elizabeth A
authors.initials: EA
authors.lastname: Traxler
authors.forename: Josh
authors.initials: J
authors.lastname: Tycko
authors.forename: Adam P
authors.initials: AP
authors.lastname: Wojno
authors.forename: James M
authors.initials: JM
authors.lastname: Wilson
mesh_terms: D000818:Animals; D002986:Clinical Trials as Topic; D000229:Dependovirus / Q000235:genetics; D004353:Drug Evaluation, Preclinical; D015316:Genetic Therapy; D005822:Genetic Vectors / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D008072:Hyperlipoproteinemia Type I / Q000378:metabolism / Q000473:pathology / Q000628:therapy; D008071:Lipoprotein Lipase / Q000172:deficiency / Q000235:genetics / Q000378:metabolism*
chemical_list: D008071:Lipoprotein Lipase